|
Video: What is a Stock Split?
|
|
Merrimack Pharmaceuticals is a biopharmaceutical company. Co. does not have any ongoing research or development activities. According to our MACK split history records, Merrimack Pharmaceuticals has had 2 splits. | |
|
Merrimack Pharmaceuticals (MACK) has 2 splits in our MACK split history database. The first split for MACK took place on September 06, 2017. This was a 1 for 10 reverse split, meaning for each 10 shares of MACK owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. MACK's second split took place on September 06, 2019. This was a 1271 for 1000 split, meaning for each 1000 shares of MACK owned pre-split, the shareholder now owned 1271 shares. For example, a 100 share position pre-split, became a 127.1 share position following the split.
When a company such as Merrimack Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. When a company such as Merrimack Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MACK split history from start to finish, an original position size of 1000 shares would have turned into 127.1 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Merrimack Pharmaceuticals shares, starting with a $10,000 purchase of MACK, presented on a split-history-adjusted basis factoring in the complete MACK split history.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
10/07/2014 |
|
End date: |
05/28/2024 |
|
Start price/share: |
$63.18 |
|
End price/share: |
$15.13 |
|
Starting shares: |
158.28 |
|
Ending shares: |
654.87 |
|
Dividends reinvested/share: |
$25.40 |
|
Total return: |
-0.92% |
|
Average Annual Total Return: |
-0.10% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$9,903.95 |
|
Years: |
9.65 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/07/2014 |
|
End date: |
05/28/2024 |
|
Start price/share: |
$63.18 |
|
End price/share: |
$15.13 |
|
Dividends collected/share: |
$25.40 |
|
Total return: |
-35.85% |
|
Average Annual Total Return: |
-4.50% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$6,413.59 |
|
Years: |
9.65 |
|
|
|
Date |
Ratio |
09/06/2017 | 1 for 10 | 09/06/2019 | 1271 for 1000 |
|
|